Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practiceReport as inadecuate




Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice - Download this document for free, or read online. Document in PDF available to download.

Journal of Hematology and Oncology

, 8:92

First Online: 28 July 2015Received: 24 June 2015Accepted: 02 July 2015DOI: 10.1186-s13045-015-0183-8

Cite this article as: Goel, G. & Sun, W. J Hematol Oncol 2015 8: 92. doi:10.1186-s13045-015-0183-8

Abstract

The recent FDA approval of ramucirumab RAISE trial has added a third agent to our existing armamentarium of angiogenesis inhibitors bevacizumab and ziv-aflibercept for the second-line treatment of metastatic colorectal cancer, which may have some impacts in the current clinic practice.

KeywordsAnti-angiogenesis Ramucirumab Bevacizumab Ziv-aflibercept Colorectal cancer  Download fulltext PDF



Author: Gaurav Goel - Weijing Sun

Source: https://link.springer.com/







Related documents